MedicaidPrior AuthMedium impact
Beleodaq® (belinostat)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Aug 12, 2026
Summary
Humana Medicaid Louisiana implemented a new prior authorization requirement for Beleodaq (belinostat) effective January 1, 2026. The policy covers only relapsed or refractory peripheral T-cell lymphoma (PTCL) and excludes patients with prior disease progression on Beleodaq or concurrent use of romidepsin, vorinostat, or pralatrexate. Initial and renewal approvals are valid for 6 months.
Action Required
By December 31, 2025: Billing team must implement prior authorization workflow for Beleodaq (belinostat) IV infusions under Humana Medicaid Louisiana. (1) Update billing system to flag all Beleodaq claims for Louisiana Medicaid requiring prior auth submission. (2) Providers must document diagnosis of relapsed or refractory PTCL and confirm patient is not on concomitant Istodax, Zolinza, or Folotyn therapy before submitting for approval. (3) Configure system to approve initially for 6 months with automatic renewal tracking at 6-month intervals. (4) Training: Inform oncology billing staff and providers that claims without prior authorization will be denied. (5) Obtain authorization before medication dispensing or IV administration to prevent claim rejections and service delays.